GT Biopharma, Inc. (GTBP) vs DataMEDS AI, Inc. (MEDS)
A side-by-side comparison of GT Biopharma, Inc. and DataMEDS AI, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GTBP
GT Biopharma, Inc.
$6.37HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
MEDS
DataMEDS AI, Inc.
$3.07HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — GTBP vs MEDS
growth of $100 · dividends reinvested · last 10yGTBP -100.0% (-69.0%/yr)MEDS -94.7% (-25.4%/yr)MEDS compounded faster over this window
Log scale — wide-divergence pair
GTBP MEDS
GTBP vs MEDS: by the numbers
- •MEDS is the larger company ($8M vs $8M market cap).
- •Both run net losses; GTBP's is the smaller (0.00% vs -1100.30% net margin).
Metrics side by side
Valuation
| Metric | GTBP | MEDS |
|---|---|---|
| P/S ratio | N/A | 1.00 |
| P/B ratio | 2.25 | N/A |
Profitability
| Metric | GTBP | MEDS |
|---|---|---|
| Gross margin | 0.00% | -41.30% |
| Operating margin | 0.00% | -347.91% |
| Net margin | 0.00% | -1100.30% |
| ROE | -618.74% | N/A |
| ROIC | -457.75% | -439.90% |
Growth (annualized)
| Metric | GTBP | MEDS |
|---|---|---|
| Total return CAGR (5Y) | -73.13% | -45.88% |
Frequently asked
- How have GTBP and MEDS total returns compared?
- Over the past 10 years, GTBP delivered -68.76% and MEDS delivered -25.43% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.